13 May 2022 - Mitsubishi Tanabe Pharma Canada announced today that Health Canada has accepted the filing of a supplement to a new drug submission for an investigational oral formulation of edaravone (MT-1186) indicated for the treatment of amyotrophic lateral sclerosis.
Health Canada has also granted a priority review, which is expected to expedite the review timelines.